 |
 |
 |
 |
 |
 |
 |
|
Press Releases
DEVELOPMENT OF NOVEL HYPERGLYGOSYLATED TYPE 1 INTERFERONS: A STRATEGY TO IMPROVE PK PERFORMANCE WITHOUT LOSS OF BIOLOGICAL POTENCY
Alios BioPharma Licenses RNase L Activators from Cleveland Clinic for Antiviral and Anticancer Therapeutics
-- Company Plans to Develop New Class of Broad Spectrum Drugs for the Treatment of Viral Diseases and Cancer --
|
